European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk
Publication
, Journal Article
Landmesser, U; John Chapman, M; Farnier, M; Gencer, B; Gielen, S; Hovingh, GK; Lüscher, TF; Sinning, D; Tokgözoğlu, L; Wiklund, O; Zamorano, JL ...
Published in: European Heart Journal
October 27, 2016
Duke Scholars
Published In
European Heart Journal
DOI
EISSN
1522-9645
ISSN
0195-668X
Publication Date
October 27, 2016
Start / End Page
ehw480 / ehw480
Publisher
Oxford University Press (OUP)
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Landmesser, U., John Chapman, M., Farnier, M., Gencer, B., Gielen, S., Hovingh, G. K., … Catapano, A. L. (2016). European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. European Heart Journal, ehw480–ehw480. https://doi.org/10.1093/eurheartj/ehw480
Landmesser, Ulf, M. John Chapman, Michel Farnier, Baris Gencer, Stephan Gielen, G Kees Hovingh, Thomas F. Lüscher, et al. “European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk.” European Heart Journal, October 27, 2016, ehw480–ehw480. https://doi.org/10.1093/eurheartj/ehw480.
Landmesser U, John Chapman M, Farnier M, Gencer B, Gielen S, Hovingh GK, et al. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. European Heart Journal. 2016 Oct 27;ehw480–ehw480.
Landmesser, Ulf, et al. “European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk.” European Heart Journal, Oxford University Press (OUP), Oct. 2016, pp. ehw480–ehw480. Crossref, doi:10.1093/eurheartj/ehw480.
Landmesser U, John Chapman M, Farnier M, Gencer B, Gielen S, Hovingh GK, Lüscher TF, Sinning D, Tokgözoğlu L, Wiklund O, Zamorano JL, Pinto FJ, Catapano AL. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. European Heart Journal. Oxford University Press (OUP); 2016 Oct 27;ehw480–ehw480.
Published In
European Heart Journal
DOI
EISSN
1522-9645
ISSN
0195-668X
Publication Date
October 27, 2016
Start / End Page
ehw480 / ehw480
Publisher
Oxford University Press (OUP)
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology